Charles N. Landen

Papers

Total Citations

H-Index

About

Charles N. Landen is a leading figure in gynecologic oncology, whose research has fundamentally advanced the understanding and treatment of ovarian and other gynecologic cancers. His work spans the molecular mechanisms of tumor progression, drug resistance, and the clinical translation of novel therapies. Landen’s major contributions include pioneering studies on the role of EphA2 and other receptor tyrosine kinases in ovarian cancer metastasis, as well as the development of targeted nanoparticle-based therapies to overcome chemoresistance. His highly cited papers—many accruing hundreds of citations—have shaped the field, particularly his seminal work on the tumor microenvironment and the role of cancer stem cells in disease recurrence. Notably, his research on EphA2-targeted therapy has led to early-phase clinical trials, bridging bench to bedside. Landen is also recognized for his leadership in cooperative group trials and his mentorship of a generation of oncologists. With a citation count exceeding 10,000, his work continues to influence both basic science and clinical practice, making him a pivotal voice in the fight against gynecologic malignancies.